Research area · Aging-biology research

Peptides and longevity research, without promises

Aging-biology research asks how aging works in cells and animals. Two peptides people often ask about here are epitalon and MOTS-c. We make no statement about their effects on aging in people. If you searched for “peptides for longevity”, this is the page for that research area.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
2 compoundsPreclinical · Review in progress
Updated Nov 2026Dated on every page
EPITALON MOTS-C
Short answerResearch area · Updated 18 Nov 2026

Epitalon and MOTS-c are two peptides people often ask about in connection with aging. No study we have reviewed shows an effect on aging in people, and neither compound is approved by the FDA. The MOTS-c studies in our register are in mice and in cells; our review of epitalon's human research is not finished.

The research so far

What has been studied

The MOTS-c studies in our register are in mice and in cells. A phase 2 trial in people is registered and recruiting; no trial giving MOTS-c to people has published results. [1] [6]

In July 2026 the FDA's compounding advisory committee voted to recommend adding epitalon to the 503A bulks list, against FDA staff's proposal. The October 2026 HHS policy covers it under ten conditions. An advisory vote is not a rule, and the policy is not an approval. [2] [5] [3]

What can’t we say about epitalon and MOTS-c?

Saying what we don't know is part of the evidence.

Any effect on aging in people. No study we have reviewed shows one, and our review of epitalon's human research is not finished.

That either compound is approved by the FDA. Neither is.

Are epitalon and MOTS-c FDA-approved medicines? US and sport status

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
EpitalonNot approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetNot named; S0 covers unapproved substances
MOTS-cNot approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S4.4.1, named)

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Does any peptide on this page slow aging in people?

We make no such statement. No study we have reviewed shows an effect on aging in people, and neither compound is approved by the FDA.

Is NAD+ a peptide?

No. NAD+ is a coenzyme made of two nucleotides, not a chain of amino acids. Our NAD+ guide explains what it is and where regulators stand.

Sources

  1. Lee C, et al. [Cell and mouse study of MOTS-c, a peptide encoded in mitochondrial DNA.] Cell Metab. 2015;21(3):443–454. PMID 25738459. doi.org/10.1016/j.cmet.2015.02.009
  2. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  3. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  4. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  5. U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  6. ClinicalTrials.gov. NCT07505745: placebo-controlled phase 2 trial of MOTS-c in adults with prediabetes and overweight or obesity (recruiting; no results). clinicaltrials.gov/study/NCT07505745

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only